STAT3 and neoplasm: Lu et al[98] experimentally found that notoginsenoside R1 counteracted OS cell-mesenchymal stem cell-induced tumorigenesis in OS cells by blocking JAK2/STAT3 signaling pathway, decreasing OS cell viability and increasing Caspase-3/9 activity in cells, inhibiting inflammatory molecule IL-6 secretion, and regulating the function of OS and tumor microenvironment.